# GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

> **NCT06379113** · PHASE2,PHASE3 · RECRUITING · sponsor: **Xiaojun Chen** · enrollment: 29 (estimated)

## Conditions studied

- Endometrial Neoplasms
- Atypical Endometrial Hyperplasia
- Progesterone Resistance
- Obesity

## Interventions

- **DRUG:** GnRH antagonist
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT06379113
- **Lead sponsor:** Xiaojun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2026-03-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06379113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06379113, "GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06379113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*